Limits...
A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants.

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz DA, Orban T, Eisenbarth G, Diabetes Prevention Trial–Type 1 and Type 1 Diabetes TrialNet Study Grou - Diabetes Care (2011)

Bottom Line: In contrast, both IA-2A positivity and titers increased substantially (P < 0.001).The same patterns of change were also evident among those positive for both autoantibodies (n = 48) at baseline.IA-2A titers increase during the years before the diagnosis of T1D, even among those positive for IA-2A.

View Article: PubMed Central - PubMed

Affiliation: ivision of Endocrinology, University of Miami, Miami, Florida, USA. jsosenko@med.miami.edu

ABSTRACT

Objective: We examined changes in GAD65 and ICA-512 autoantibodies (GADA and IA-2A) during progression to type 1 diabetes (T1D).

Research design and methods: Diabetes Prevention Trial-Type 1 (DPT-1) participants were assessed for changes in positivity and titers of GADA and IA-2A during the progression to T1D.

Results: Among 99 progressors to T1D with GADA and IA-2A measurements at baseline and diagnosis (mean interval = 3.3 ± 1.5 years), GADA positivity changed little and GADA titers decreased (P < 0.01). In contrast, both IA-2A positivity and titers increased substantially (P < 0.001). Even among those positive at baseline, IA-2A titers increased from baseline to diagnosis (n = 57; P < 0.001), whereas GADA titers decreased (n = 80; P < 0.01). The same patterns of change were also evident among those positive for both autoantibodies (n = 48) at baseline.

Conclusions: IA-2A titers increase during the years before the diagnosis of T1D, even among those positive for IA-2A. In contrast, GADA titers tend to decline during those years.

Show MeSH

Related in: MedlinePlus

Shown are titers of GADA (A) and IA-2A (B) at baseline (mean ± SD: 3.3 ± 1.5 years before diagnosis) and at diagnosis in the same individuals. Whereas there tends to be a decrease in the GADA titer, the IA-2A titer increases. White line, median; vertical line, range; bottom of box, 25th percentile; top of box, 75th percentile.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3198298&req=5

Figure 1: Shown are titers of GADA (A) and IA-2A (B) at baseline (mean ± SD: 3.3 ± 1.5 years before diagnosis) and at diagnosis in the same individuals. Whereas there tends to be a decrease in the GADA titer, the IA-2A titer increases. White line, median; vertical line, range; bottom of box, 25th percentile; top of box, 75th percentile.

Mentions: Figure 1 shows that GADA titers (Fig. 1A) declined (P < 0.01), whereas IA-2A titers (Fig. 1B) increased (P < 0.001) from baseline to diagnosis. When the parenteral (n = 51) and oral (n = 48) trials were analyzed separately for titers, the same difference in directionality was evident (parenteral: P = 0.14 for GADA, P < 0.001 for IA-2A; oral: P < 0.05 for GADA, P < 0.001 for IA-2A).


A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants.

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz DA, Orban T, Eisenbarth G, Diabetes Prevention Trial–Type 1 and Type 1 Diabetes TrialNet Study Grou - Diabetes Care (2011)

Shown are titers of GADA (A) and IA-2A (B) at baseline (mean ± SD: 3.3 ± 1.5 years before diagnosis) and at diagnosis in the same individuals. Whereas there tends to be a decrease in the GADA titer, the IA-2A titer increases. White line, median; vertical line, range; bottom of box, 25th percentile; top of box, 75th percentile.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3198298&req=5

Figure 1: Shown are titers of GADA (A) and IA-2A (B) at baseline (mean ± SD: 3.3 ± 1.5 years before diagnosis) and at diagnosis in the same individuals. Whereas there tends to be a decrease in the GADA titer, the IA-2A titer increases. White line, median; vertical line, range; bottom of box, 25th percentile; top of box, 75th percentile.
Mentions: Figure 1 shows that GADA titers (Fig. 1A) declined (P < 0.01), whereas IA-2A titers (Fig. 1B) increased (P < 0.001) from baseline to diagnosis. When the parenteral (n = 51) and oral (n = 48) trials were analyzed separately for titers, the same difference in directionality was evident (parenteral: P = 0.14 for GADA, P < 0.001 for IA-2A; oral: P < 0.05 for GADA, P < 0.001 for IA-2A).

Bottom Line: In contrast, both IA-2A positivity and titers increased substantially (P < 0.001).The same patterns of change were also evident among those positive for both autoantibodies (n = 48) at baseline.IA-2A titers increase during the years before the diagnosis of T1D, even among those positive for IA-2A.

View Article: PubMed Central - PubMed

Affiliation: ivision of Endocrinology, University of Miami, Miami, Florida, USA. jsosenko@med.miami.edu

ABSTRACT

Objective: We examined changes in GAD65 and ICA-512 autoantibodies (GADA and IA-2A) during progression to type 1 diabetes (T1D).

Research design and methods: Diabetes Prevention Trial-Type 1 (DPT-1) participants were assessed for changes in positivity and titers of GADA and IA-2A during the progression to T1D.

Results: Among 99 progressors to T1D with GADA and IA-2A measurements at baseline and diagnosis (mean interval = 3.3 ± 1.5 years), GADA positivity changed little and GADA titers decreased (P < 0.01). In contrast, both IA-2A positivity and titers increased substantially (P < 0.001). Even among those positive at baseline, IA-2A titers increased from baseline to diagnosis (n = 57; P < 0.001), whereas GADA titers decreased (n = 80; P < 0.01). The same patterns of change were also evident among those positive for both autoantibodies (n = 48) at baseline.

Conclusions: IA-2A titers increase during the years before the diagnosis of T1D, even among those positive for IA-2A. In contrast, GADA titers tend to decline during those years.

Show MeSH
Related in: MedlinePlus